Interested in joining our team? https://lnkd.in/eU2DqnZf
Eliksa Therapeutics
Biotechnology Research
Doylestown, Pennsylvania 1,185 followers
The Future of Regenerative Medicine
About us
Eliksa Therapeutics is a venture-backed biotechnology company with a proprietary cGMP production facility and a robust clinical pipeline addressing unmet medical needs in ocular and cardiovascular indications. Our lead candidate, ELK-003, is a novel multi-target biological modulating inflammation, cell recovery, and tissue healing. ELK-003 has proven to be safe and well-tolerated with 18,000+ human doses without any reported side effects.
- Website
-
http://www.eliksa.com
External link for Eliksa Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Doylestown, Pennsylvania
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
3805 Old Easton Rd
Doylestown, Pennsylvania 18902, US
-
Get directions
675 Arapeen Dr
Salt Lake City, Utah 84108, US
Employees at Eliksa Therapeutics
Updates
-
Make a difference! Join our team!
🌟 We're Hiring a Project Manager at Eliksa Therapeutics! 🌟 As our Project Manager, you'll lead crucial phases of late preclinical and early clinical development for our biological drug aimed at treating ocular manifestations of epidermolysis bullosa #EB. This is a unique chance to influence the project's direction from an early stage, with ample opportunities for professional growth in a supportive and innovative environment. Apply here The O'Connor Group: https://lnkd.in/dcbmM_fg
-
Welcome Biplav Shrestha to Eliksa Therapeutics!
-
-
Today, on Rare Disease Day, we had the honor of visiting Fundación DEBRA Chile-Niños Piel de Cristal, marking a significant milestone in our ongoing collaboration, as we move closer to launching the first clinical trial for ocular manifestations of epidermolysis bullosa. #RareDiseaseDay #EBawareness
-
-
Thank you to debra of America for honoring us with the Partners in Progress Award recognizing our efforts in developing ELK-003, a novel eye drop for treating the ocular manifestations of Epidermolysis Bullosa. Special thanks to the incredible Eliksa Therapeutics team whose unwavering dedication and collaborative spirit made this achievement possible. #epidermolysisbullosa #eb
-
-
We are honored to receive this award from debra of America for our groundbreaking work in developing a novel eye drop (ELK-003) to treat ocular manifestation of Epidermolysis Bullosa. At Eliksa Therapeutics, our dedication to improving the lives of EB patients drives us forward, and ELK-003 represents a major step in our ongoing journey to make a meaningful impact in their ocular treatment and well-being. #EpidermolysisBullosa #EB
Announcing our 2023 Partners in Progress Award Honoree: Eliksa Therapeutics! ✨🎉 Eliksa is developing the first-ever eye drop (ELK-003) to treat corneal abrasions in those with Epidermolysis Bullosa (EB). Join us on November 4, 2023 at Georgia Aquarium to honor our friends at Eliksa at the #debraBenefit! ➡️ Learn more about Eliksa and their work at https://lnkd.in/gj5vn9ze
-